A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.

A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.

T here's always a new headline about weight-loss drugs, whether it's sharing new data on how many pounds someone has lost or a newly discovered side effect. Either way, there's no

It has the most potent weight-loss shot and a large experimental pipeline, including what is widely expected to be the first approved small molecule GLP-1 pill.

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.